Action MYGN MYRIAD GENETICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Myriad Genetics, Inc.

Actions

MYGN

US62855J1043

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 15/07/2024 		Varia. 5j. Varia. 1 janv.
26,64 USD +0,83 % Graphique intraday de Myriad Genetics, Inc. +5,46 % +39,18 %
11/07 Myriad Genetics et Personalis accordent des licences croisées sur la propriété intellectuelle des tests de détection de la maladie résiduelle minimale MT
11/07 Myriad Genetics, Inc. et Personalis, Inc. accordent des licences croisées sur la propriété intellectuelle fondamentale en matière de MRD afin d'élargir l'accès des patients aux tests CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Myriad Genetics, Personalis to Cross-License IP on Minimal Residual Disease Tests
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Myriad Genetics, Inc. and Personalis, Inc. Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Myriad Genetics Receives New US Patent for Molecular Residual Disease Technology
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics Earns 2024 Great Place To Work® Certification™
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
Myriad Genetics, GSK Partner to Expand Access to HRD Diagnostic Testing
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
NOTICE OF PENDENCY OF SETTLEMENT OF DERIVATIVE LITIGATION TO: ALL CURRENT STOCKHOLDERS OF MYRIAD GENETICS, INC. (NASDAQ SYMBOL: MYGN) - Form 8-K
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
QIAGEN and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MYGN
  4. Actualités Myriad Genetics, Inc.
  5. Autres langues